IO Biotech Inc
IOBT
查看詳細走勢圖
0.664USD
+0.042+6.83%
收盤 12/19, 16:00（美東）報價延遲15分鐘
46.31M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+6.83%
5天
-17.72%
1月
-10.06%
6月
-48.88%
今年開始到現在
-27.77%
1年
-13.81%
查看詳細走勢圖
TradingKey IO Biotech Inc股票評分
單位: USD 更新時間: 2025-10-27操作建議
當前估值低估，機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間，可以做區間波段操作。
IO Biotech Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
6
分析師
買入
評級
2.463
目標均價
+227.70%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
IO Biotech Inc亮點
亮點風險
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
利潤高增長
公司淨利潤處於行業前列，最新年度總收入0.00美元
估值高估
公司最新PE估值-0.58，處於3年歷史高位
機構減倉
最新機構持股42.06M股，環比減少24.13%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉139.30K股
活躍度增加
近期活躍度增加，過去20天平均換手率13.93
IO Biotech Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
IO Biotech Inc簡介
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
公司代碼IOBT
公司IO Biotech Inc
CEOZocca (Mai-Britt)
網址https://www.iobiotech.com/
常見問題
IO Biotech Inc(IOBT)的當前股價是多少？
IO Biotech Inc(IOBT)的當前股價是 0.664。
IO Biotech Inc 的股票代碼是什麼？
IO Biotech Inc的股票代碼是IOBT。
IO Biotech Inc股票的52週最高點是多少？
IO Biotech Inc股票的52週最高點是2.790。
IO Biotech Inc股票的52週最低點是多少？
IO Biotech Inc股票的52週最低點是0.323。
IO Biotech Inc的市值是多少？
IO Biotech Inc的市值是46.31M。
IO Biotech Inc的淨利潤是多少？
IO Biotech Inc的淨利潤為-95.49M。
現在IO Biotech Inc(IOBT)的股票是買入、持有還是賣出？
根據分析師評級，IO Biotech Inc(IOBT)的總體評級為買入，目標價格為2.463。
IO Biotech Inc(IOBT)股票的每股收益（EPS TTM）是多少
IO Biotech Inc(IOBT)股票的每股收益（EPS TTM）是-1.336。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
